Bioscript strengthens evidence-generation capability with acquisition of Triducive

Bioscript Group, the specialist healthcare communications and scientific services group backed by Sovereign Capital Partners, has completed the acquisition of Triducive Partners, a consultancy that helps pharmaceutical and life sciences companies gather and publish expert clinical opinion to support the adoption of new treatments.

Founded in 2009 and based in St Albans, Hertfordshire, Triducive works with many of the world's leading pharmaceutical companies, including AstraZeneca and Johnson & Johnson. Co-founders Tim Warren and Nick Williams will remain with the business, ensuring continuity for clients as Triducive integrates into Bioscript's Data and Insights division.

Triducive is the fifth acquisition completed by Bioscript since Sovereign invested in the business in 2021, following Fortis, Valid Insight, Meridian and Enzyme Communications. The addition further strengthens Bioscript's ability to support clients across the full medical affairs value chain, from evidence generation through to publication, advisory boards and scientific communications.

Dominic Dalli, Managing Partner, Sovereign Capital Partners, said: "Triducive is a high-quality addition that meaningfully strengthens Bioscript's proposition. Their expertise in distilling expert clinical consensus sits at the upstream end of the medical affairs value chain, and combining it with Bioscript's communications platform creates a compelling, integrated offering for clients."

Gabrielle Silver, CEO, Bioscript Group, said: "Triducive brings exceptional strength in generating the kind of structured, practice‑based insights that help clients understand what truly influences clinical and policy decision‑making. By combining this with Bioscript’s strategic communications expertise, we can support clients with programmes grounded in real world experience."

Tim Warren, Managing Partner, Triducive, said: "Joining Bioscript Group gives us the platform to broaden the impact of our work. The ability to pair our insight generation with Bioscript’s communications expertise will enable clients to translate evidence into action more effectively and with greater reach. The alignment of values and ambition makes this an exciting partnership for our team and our clients."